Objective To determine the ability of CSF biomarkers to predict disease progression in progressive supranuclear palsy (PSP).
Progressive supranuclear palsy (PSP) has been a focus of tau biomarker and anti-tau therapeutic development due to the high correlation between its classical phenotype, now called Richardson syndrome (PSP-RS), and PSP pathology, involving a characteristic pattern of 4 microtubule binding repeat (4R) tau deposition in various brain regions and strong genetic links to tau gene (MAPT) polymorphisms. [1] [2] [3] [4] In Alzheimer disease (AD), elevated CSF total tau and phosphorylated tau 181 (ptau) and decreased β-amyloid 1-42 (Aβ42) are useful for diagnosis and as pharmacodynamic biomarkers in clinical trials. 5 In PSP, however, despite strong links to tau, CSF tau and p-tau concentrations are often lower than in age-matched controls, and do not change over the course of 1 year. [6] [7] [8] An unresolved question is whether lower CSF tau and p-tau concentrations have clinical significance in PSP, similar to low Aβ42 for AD. To date, the only CSF analyte that displays clear clinical correlates in PSP is neurofilament light chain (NfL). NfL was the only fluid biomarker to show longitudinal changes correlating with clinical and regional MRI volume changes in a recent PSP clinical trial. 6 Although recent studies have demonstrated the potential utility of using plasma NfL to diagnose PSP and predict disease progression, [9] [10] [11] [12] CSF analyte concentrations generally have stronger relationships to clinical features of other disorders. 13 The goal of this study was to determine the clinical correlates of CSF NfL, Aβ42, tau and p-tau, and plasma NfL and their ability to predict disease progression using data from a well-characterized PSP clinical trial cohort.
Methods

Patients
Historical data were taken from the previously reported AL-108-231 international, randomized, double-blind, placebo-controlled, phase 2/3 trial of davunetide for PSP (clinicaltrials.gov, NCT 01110720). 6 This trial enrolled 313 patients meeting clinical criteria for PSP-RS at 48 centers in Australia, Canada, France, Germany, the United Kingdom, and the United States. In the current study, 2 subgroups were analyzed: one with available CSF (n = 50) and another previously reported with available plasma (n = 141).
11 Twenty-two patients had both CSF and plasma samples (figure e-1, links.lww.com/WNL/A66).
Standard protocol approvals, registrations, and patient consents
Patients provided informed consent at the time of recruitment and procedures were approved by local ethics committees. 6 Clinical evaluation See supplemental Methods, links.lww.com/WNL/A68.
The Mini-Mental State Examination (MMSE) 14 was obtained at baseline. Neurologic assessments were based on the Progressive Supranuclear Palsy Rating Scale (PSPRS). 15 The Repeatable Battery for the Assessment of Neuropsychological Disease Severity (RBANS) 16 ) were used to measure neuropsychological status. The color trails test is a language-free version of the trails-making test. It consists of part 1 (CTT1) and part 2 (CTT2), which measure sustained attention and set-shifting, respectively. Assessment of overall disability relied on the Schwab and England Activities of Daily Living (SEADL) scale and a global measure of disease severity was obtained with the Clinical Global Impression of Severity (CGI-S). 20 PSPRS and SEADL scores were obtained at baseline, 6-, 13-, 26-, 39-, and 52-week visits. Each of these time points is referred to as an interval. The RBANS and measures of executive function were obtained at baseline, 26-, and 52-week visits. The CGI-S was obtained at baseline and week 52.
Biomarkers CSF and plasma collections were performed according to the Alzheimer's Disease Neuroimaging Initiative protocol at baseline and week 52. 21 The INNO-BIA AlzBio3 (Fujirebio, Gent, Belgium) platform was used to measure CSF Aβ42, tau, and p-tau. CSF NfL concentrations were measured using the Uman Diagnostics (Umea, Sweden) ELISA kit (NFLight kit). For NfL measurements, samples were diluted 4× prior to running the assay and then a correction factor of 4 was used to determine final concentration. All Alzbio3 and NfL analyses were performed in duplicate by a centralized laboratory. Plasma NfL concentrations were determined using the NF-Light kit transferred onto the Simoa platform using a homebrew kit (Quanterix, Boston, MA) as previously described.
11
MRI data Whole-brain, ventricular, midbrain, and superior cerebellar peduncle (SCP) volumetric measures obtained from 1.5T or 3T structural MRI scans at baseline and week 52 were available in 127 of 141 cases with available plasma and in 46 of 50 with available CSF (figure e-1, links.lww.com/WNL/A66). The magnet strength was determined by site availability and Glossary 4R = 4 microtubule binding repeat; Aβ42 = β-amyloid ; AD = Alzheimer disease; CGI-S = Clinical Global Impression of Severity; CI = confidence interval; CTT1 = color trails test 1; CTT2 = color trails test 2; FDR = false discovery rate; LNS = letter-number sequencing; MMSE = Mini-Mental State Examination; NfL = neurofilament light chain; p-tau = phosphorylated tau 181; PSP = progressive supranuclear palsy; PSP-RS = progressive supranuclear palsy-Richardson syndrome; PSPRS = Progressive Supranuclear Palsy Rating Scale; RBANS = Repeatable Battery for the Assessment of Neuropsychological Disease Severity; SCP = superior cerebellar peduncle; SEADL = Schwab and England Activities of Daily Living. no patients switched scanners during the study. 22 MRI scans met standards established by the Mayo Clinic's Aging and Dementia Imaging Research Laboratory and volumetric data were generated using the Boundary Shift Integral technique or label propagation in voxel-based morphometry (SPM5) as previously described. 6 
Statistical analyses
Baseline values were compared to those at 52 weeks using Wilcoxon signed rank test. Tests for normality were conducted with the Shapiro-Wilk test. Biomarker data were logtransformed prior to further analyses because they were not normally distributed. Initial exploratory analyses included Pearson product-moment correlations between baseline or 52-week change in CSF biomarker concentrations (Aβ42, tau, ptau, NfL, p-tau/tau, Aβ42/tau, Aβ42/p-tau, NfL/tau, and NfL/ p-tau) and baseline or 52-week change in clinical scores and brain volumes. SEADL and CGI-S were analyzed with Spearman rank correlations but considered equivalent to Pearson correlations for false discovery rate (FDR) adjustment purposes. Linear mixed effects analyses controlling for age, sex, and baseline MMSE were used to determine the ability of baseline CSF biomarkers to predict a change in clinical measures over 6, 13, 26, 39, and 52 weeks. Dependent variables included SEADL, CGI-S, PSPRS, RBANS, color trails, LNS, and phonemic fluency scores. Mixed linear models examining the ability of CSF biomarkers to predict changes in volumetric MRI data (whole-brain, ventricular, midbrain, and SCP volumes) were corrected for magnet strength and total intracranial volume, instead of MMSE. Separate models examined the effect of including baseline PSPRS score as a covariate. A compound symmetry repeated covariance matrix was used in all models and biomarker values were mean-centered. To account for the effect of baseline values, a term for biomarker by time interaction was introduced in addition to the random intercepts. In a first set of analyses, baseline CSF biomarker values were entered as continuous predictor variables. In a second set of analyses, and to test whether biomarker cutoff values could discriminate patients with a faster decline, baseline CSF biomarker values were entered as categorical variables, dichotomized at the 50th percentile value. Similar analyses were conducted with baseline plasma NfL as a predictor variable. To test the superiority of biomarkers to predict outcomes and to test for the value of combining different biomarkers in a ratio, the significance of the difference between F values from 2 given mixed linear models was computed with the Fisher distribution variance ratios. For all analyses, we accepted a p < 0.05, corrected for multiple comparisons across all dependent variables for a given biomarker, using FDR. 23 Data were analyzed using SPSS (version 24; SPSS/IBM, Chicago, IL).
Results
Baseline associations of CSF analytes with clinical and imaging variables
At baseline, CSF p-tau and NfL, but not Aβ42 or tau, correlated with clinical, neuropsychological, and volumetric MRI measures (table 1 and figures e-2 to e-10, links.lww.com/ WNL/A66). Biomarker ratios containing p-tau or NfL, except for p-tau/tau, correlated with clinical, executive, or volumetric variables. NfL was the only biomarker that changed median values over time (18% increase in CSF, p = 0.005, and 13% increase in plasma, p < 0.001, Wilcoxon test). CSF and plasma NfL concentrations were correlated (r = 0.64, p = 0.001). Although correlations between the annual change in NfL concentrations and the change in clinical variables have been previously reported, 6 no such correlations were observed in this smaller sample for any of the biomarkers.
Baseline CSF values predict longitudinal change Baseline CSF NfL, p-tau, and tau were strong predictors of the rate of change in clinical variables over 52 weeks. Biomarker concentration by time interactions were observed with higher CSF NfL concentration as a predictor of faster annual worsening in PSPRS (2. Baseline plasma NfL concentration interacted with time as a predictor of faster disease progression measured by PSPRS (1.8 points per log plasma NfL pg/mL increase per interval, 95% CI 0.94-2.7, p < 0.008), SEADL (−0.02 points per log plasma NfL pg/mL increase per interval, 95% CI −0.04 to −0.007, p = 0.012), and RBANS (−6.3 points per log plasma NfL pg/mL increase per interval, 95% CI −9.6 to −3.0, p < 0.004). Plasma NfL was a superior predictor of the annual rate of change of RBANS (p = 0.004) and PSPRS (p = 0.016) compared to CSF NfL (table e-1, links.lww.com/WNL/A67). For PSPRS, this superiority was not attributable to the higher number of available plasma samples, since the difference remained after a comparison was run only in cases with available CSF and plasma (n = 22, p = 0.015). In this smaller sample, no difference was observed between plasma and CSF NfL for the prediction of RBANS (n = 22, p = 0.160).
Median baseline CSF analyte values identify patients with more severe disease To test whether biomarker threshold values could identify patients with different rates of decline, patients were grouped based on a median split in biomarker concentration. No 
(A-C) PSPRS as a function of baseline biomarker concentration (log transformed, ng/mL) from linear mixed effects models. Each patient's longitudinal PSPRS scores appear as a vertical array of dots of increasing saturation (lightest at baseline to darkest at 52 weeks). Each individual's rate of change in PSPRS scores is depicted by the vertical distance between dots. In the examples within the purple rectangles in B and C, the rate of change is small at either high CSF phosphorylated tau 181 (p-tau) (≈log 1.8 or 63 ng/mL) or low neurofilament light chain (NfL) (≈log 3.2 or 1,600 ng/mL) concentrations (*), whereas it is relatively higher at low p-tau (≈log 1.2 or 16 ng/mL) and high NfL (≈log 4.5 or 31,600 ng/mL) (**), reflecting a time by biomarker interaction. There was no relationship between baseline CSF tau and rate of PSPRS change (A). 
Discussion
We found that baseline concentrations of NfL, in CSF or plasma, and CSF p-tau were useful predictors of rates of change in clinical and neuropsychological status in PSP. These biomarkers were also associated with disease severity at baseline as reflected by clinical rating scales, neuropsychological measures of executive function scores, and SCP volume measured by MRI. Similar to studies in other diseases and a previous study of plasma NfL in PSP, 11 higher CSF NfL concentrations were associated with greater disease severity and faster rates of disease progression. These associations are important because they reflect magnitudes of difference in clinical rating scales that were previously shown to be clinically meaningful. 24 For example, the observed concentration range of CSF NfL spans 2 log units, which corresponds to a difference of about 5 points in PSPRS scores. This represents the difference between having normal gait vs being wheelchair-bound.
Unexpectedly, we found that lower p-tau concentrations were associated with greater disease severity and more aggressive disease progression on multiple rating scales. This was not the case for CSF tau concentration, for which higher baseline concentration predicted faster rates of SEADL change, but no other clinical or imaging association. Combining CSF NfL and p-tau in a ratio further increased the prediction value for change in PSPRS over either analyte alone. CSF was superior to plasma NfL concentration for stratification of baseline disease severity as measured by SEADL, CGI-S, and PSPRS, but plasma NfL was superior to CSF for predicting rates of change. These data suggest that both CSF NfL and p-tau are useful biomarkers to measure disease severity and predict change in PSP.
Our findings are consistent with previous studies demonstrating normal or low normal CSF tau and p-tau in PSP, 7, 8, 25, 26 and extend these results by demonstrating that low CSF p-tau has strong clinical correlates. Unlike in AD, where higher p-tau and tau concentrations are associated with increasing disease severity (asymptomatic vs mild cognitive impairment vs dementia) 27 and predict the development of clinical disease, 28 in PSP the opposite appears to be true. Moreover, cross-sectional correlations between CSF p-tau with clinical measures of disease severity appear to be stronger in PSP than in AD. 29 CSF Aβ42 had no predictive value in PSP, but lower p-tau concentrations were associated with greater disease severity and predicted more rapid disease progression over time, which is analogous to the association of low CSF Aβ42 as an early and persistent finding in AD. The findings suggest that although AD and PSP are both tauopathies featuring insoluble deposits of hyperphosphorylated tau in neurons (and glia in PSP) at autopsy, the mechanisms by which tau protein abnormalities either cause or reflect the underlying causes of neurodegeneration in these disorders are likely to be different. One possible explanation might be that CSF tau concentrations are related to the pathogenic tau isoforms found in each disease. In AD, both 3 and 4 microtubule binding domain repeat (3R) and 4R tau are found in neurofibrillary tangles, whereas in PSP mostly 4R tau is found deposited in neurons and glia. Another possibility is that low CSF p-tau concentrations reflect a key pathogenic mechanism in PSP that is different from AD. A genetic polymorphism near the MOBP gene that increases the risk of PSP is associated with increased caspase-mediated tau cleavage via increased expression of appoptosin, which can be detected in PSP brains at autopsy. 30 Therefore, low CSF p-tau might reflect increased tau cleavage in PSP. Finally, as tau can spread transcellularly in a prion-like fashion, and different tau prion strains may be associated with different diseases, low CSF p-tau in PSP might be a feature of a pathogenic tau prion strain found in PSP. 31 Our results support the utility of CSF and plasma NfL as PSP biomarkers. NfL is abundant in large-caliber myelinated axons, where it contributes mechanoresistance. NfL concentrations seem to reflect active neuronal injury, based on its variations that mirror acute clinical decline, such as that seen in neurodegeneration, hypoxia, and neuroinflammation. 32 Similar to AD, higher NfL concentrations were associated with worse disease and predicted faster progression. 33 Nevertheless, the dynamic range and variation rate of NfL concentrations in neurodegenerative diseases are still poorly understood.
Our study has important limitations. The findings were not replicated in an independent cohort, because a cohort with comparable characterization and biospecimen availability is difficult to build. This highlights the importance of capitalizing on the unique opportunities for biomarker discovery offered by certain study designs, such as clinical trials, especially in rare diseases. Further analysis is needed to understand the relative value of CSF and plasma NfL measures. This was limited by the relatively small number of samples, which might reflect a selection bias with retention of patients with less disability and better able to undergo lumbar puncture. The comparison between the prognostic performance of CSF and plasma NfL might also have been influenced by the use of different methodologies to measure CSF and plasma NfL concentration. 34 Insight into the dynamics of clinicalbiomarker relationships were out of the scope of the study and will require future longitudinal biomarker analyses. We did not control for white matter disease burden, which could have affected the relationships between the fluid biomarkers and MRI measures. Only patients with the classical PSP-RS phenotype were included in this study. It is uncertain how the results relate to other variant PSP phenotypes. 4 Finally, although the PSP-RS phenotype is highly specific for PSP pathology, the lack of neuropathologic data remains a relevant caveat.
This study provides strong evidence supporting the clinical relevance of NfL and p-tau for patient stratification and as predictors of neurologic, cognitive, and functional decline in clinical trials of new therapies for PSP. 
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Associations between CSF biomarkers and PSP disease progression suggest that the former might be indicative of meaningful changes in clinical scale ratings. This study demonstrates CSF p-tau and NfL correlations with PSP disease severity and progression rate.
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Two patient groups were analyzed, one comprising 50 participants with available CSF and the other 141 participants with available plasma. Twenty-two patients had both CSF and plasma samples.
Design, size, and duration Data were obtained from an international, randomized, doubleblind, placebo-controlled, phase 2/3 trial of davunetide for PSP, which enrolled 313 patients who met Progressive Supranuclear Palsy Rating Scale (PSPRS) criteria at 48 centers in Australia, Canada, France, Germany, the United Kingdom, and the United States. Clinical evaluation, biomarker collection, and MRI scans were obtained at baseline and week 52. Main results and the role of chance A rapid decline in PSPRS (p = 0.004) and SEADL (p = 0.008) was predictable via higher CSF NfL concentrations, while faster decline in PSPRS (p = 0.004) was predictable by lower baseline CSF p-tau. Faster decline in SEADL (p = 0.004) was predictable by higher CSF tau concentrations. Compared to p-tau (p = 0.003) or NfL (p = 0.001) alone, the CSF NfL/p-tau ratio was a better predictor of PSPRS changes. A correlation between higher CSF or blood NfL concentrations and greater cerebellar peduncle atrophy was observed (p = 0.029 and 0.008, respectively).
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